A U.S. Food and Drug Administration (FDA) advisory committee recently determined that phenylephrine, an ingredient commonly used to treat sinus and nasal congestion, is ineffective in treating these symptoms. This was apparent from research for years, yet large...
El senador estadounidense Marco Rubio (R-FL) habló con César Grajales de La Poderosa 670 AM en El Panorama Político, sobre la crisis fronteriza, sobre cómo los hispanoamericanos se ven afectados con la realidad del país, sobre los cargos contra el senador Bob Menéndez...
Pregnant students are sometimes discriminated against by their schools, either intentionally or unintentionally and there is a concerning lack of awareness about the resources and rights available to them. Due to a lack of services and discrimination, these women may...
Currently, intelligence community civilians are subject to certain tax penalties for job-related relocation requirements, but active-duty military servicemembers are not subjected to the same penalties. These tax benefits, including the ability to deduct moving...
Vice Chairman of the Senate Select Committee on Intelligence Marco Rubio (R-FL) delivered opening remarks and questioned witnesses at a hearing on countering China’s influence in the United States. Watch Rubio’s opening remarks here as well as Part I and Part II of...
Approximately 302,000 Americans live with spinal cord injuries. To help these people achieve a better quality of life, there is a need to increase education and invest in research. U.S. Senators Marco Rubio (R-FL) and Tammy Baldwin (D-WI) successfully led a bipartisan...
Rubio Joins Blackburn, Colleagues in Urging Regulatory Relief for Businesses
Washington, D.C. — U.S. Senator Marco Rubio (R-FL) joined Senator Marsha Blackburn (R-TN), along with 26 Republican Senate colleagues, in urging Senate leadership to provide businesses with regulatory relief in the wake of the economic crisis caused by the global COVID-19 pandemic.
“In contrast to unsustainable increases in federal spending, the easing of regulatory burdens – estimated to cost businesses as much as $1.9 trillion – will have broader macroeconomic effects by promoting competition and private investment,” the Senators wrote. “We stand ready to work with you to adopt commonsense regulatory relief in an effort to promote long-term economic recovery following the COVID-19 healthcare crisis.”
Rubio and Blackburn were joined by Senators Chuck Grassley (R-IA), Kelly Loeffler (R-GA), Ted Cruz (R-TX), Steve Daines (R-MT), David Perdue (R-GA), Joni Ernst (R-IA), Pat Toomey (R-PA), Rick Scott (R-FL), Mike Braun (R-IN), Rand Paul (R-KY), Thom Tillis (R-NC), Kevin Cramer (R-ND), Jerry Moran (R-KS), Mike Rounds (R-SD), John Hoeven (R-ND), Deb Fischer (R-NE), Mike Crapo (R-ID), James Risch (R-ID), Mike Enzi (R-WY), Mike Lee (R-UT), James Inhofe (R-OK), John Boozman (R-AR), John Barrasso (R-WY), Pat Roberts (R-KS), Dan Sullivan (R-AK), and Ben Sasse (R-NE).
The full text of the letter is below.
Dear Majority Leader McConnell and Minority Leader Schumer:
We applaud your bipartisan leadership and cooperation in responding to the unprecedented health and economic crisis that resulted from the COVID-19 pandemic. In that spirit, we write to urge the consideration of statutory changes to significantly reduce red tape, paperwork, and other regulatory requirements as an important step to respond to COVID-19 in general, and economic recovery in particular.
Since the emergence of COVID-19, there have been massive changes around the world to cope with the pandemic. Domestically, we have seen federal, state, and local governments struggle to protect at-risk populations through social distancing, mandatory business closures, and various shelter-in-place strategies. These measures do appear to help “flatten the curve” of COVID-19 infections, but they are taking a devastating toll on the economy, jobs, and people’s lives.
Since March 5, 2020, the Senate has passed four packages of legislation to respond to this extraordinary health and economic disaster. Moving forward, we must include statutory changes that permit regulatory relief for businesses small and large across every sector of the economy.
Regulatory reform, whether through paperwork reduction or removing outmoded compliance requirements, is the most efficient means of promoting economic recovery. This approach avoids the pitfalls of waste, fraud, and abuse that always accompany increased government spending. In contrast to unsustainable increases in federal spending, the easing of regulatory burdens – estimated to cost businesses as much as $1.9 trillion – will have broader macroeconomic effects by promoting competition and private investment.
Thank you for your attention to this matter. We stand ready to work with you to adopt commonsense regulatory relief in an effort to promote long-term economic recovery following the COVID-19 healthcare crisis.